摘要
目的探讨SMARCA2缺失性非小细胞肺癌(SMARCA2-dNSCLC)的临床病理特征。方法回顾性分析我院病理科确诊的8例SMARCA2-dNSCLC患者的临床资料,总结其组织病理学、免疫组织化学特征及基因突变特征,并结合文献进行复习。结果8例患者均为男性,中位年龄60岁,其中6例有吸烟史;随访1~15个月,截至末次随访,4例患者存活,4例死亡,生存时间为4~9个月。组织学显示,所有肿瘤均呈巢片状结构,细胞以上皮样形态为主;其中1例见腺样结构,5例见瘤巨细胞,6例伴有明显坏死,1例出现间质黏液样变;间质内可见不等量慢性炎细胞浸润。免疫组织化学显示,所有病例肿瘤细胞均呈SMARCA2(BRM)弥漫阴性表达,SMARCA4(BRG-1)阳性表达;3例表达甲状腺转录因子-1(TTF-1)。1例检出EGFR 19-del突变,1例检出KRAS G12C突变。结论SMARCA2-dNSCLC预后较差,SMARCA2表达缺失可作为评估预后的潜在指标。
Objective To investigate the clinicopathological features of SMARCA2-deficient non-small cell lung cancer(SMARCA2-dNSCLC).Methods The clinical data of 8 patients with SMARCA2-dNSCLC diagnosed in the pathology department of our hospital were retrospectively analyzed.The histopathological,immunohistochemical and gene mutation characteristics were summarized,and the literature was reviewed.Results All the 8 patients were male,with a median age of 60 years old,and 6 cases of them had a history of smoking;the patients were followed up for 1-15 months,up to the last follow-up,4 patients survived and 4 patients died,and the survival time was 4-9 months.Histology showed that all tumors showed a nest-like structure,and the cells were mainly epithelial-like;among them,1 case had adenoid structure,5 cases had tumor giant cells,6 cases had obvious necrosis,and 1 case had interstitial myxoid change;unequal amounts of chronic inflammatory cell infiltration were observed in the interstitium.Immunohistochemistry showed that the tumor cells in all cases showed diffuse negative expression of SMARCA2(BRM)and positive expression of SMARCA4(BRG-1);thyroid transcription factor-1(TTF-1)was expressed in 3 cases.EGFR 19-del mutation was detected in 1 case and KRAS G12C mutation was detected in 1 case.Conclusion The prognosis of SMARCA2-dNSCLC is poor,and the loss of SMARCA2 expression can be used as a potential indicator for evaluating prognosis.
作者
孟凤娇
MENG Fengjiao(Pathology Department,Zhongshan City People's Hospital,Zhongshan 528403,China)
出处
《临床医学研究与实践》
2025年第36期62-66,共5页
Clinical Research and Practice
基金
2022年度中山市医学科研项目(No.2022J115)。
